Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders

PLoS Computational Biology

Volumn 10, Issue 11, 2014, Pages

  Iturria Medina, Yasser ^a   Sotero, Roberto C ^a   Toussaint, Paule J ^a   Evans, Alan C ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEPOSITION; NEURODEGENERATIVE DISEASES; PROTEINS;

ALZHEIMERS DISEASE; CONNECTOMES; DEPOSITION PATTERNS; DISEASE PROGRESSION; EPIDEMIC SPREADING; HUMAN BRAIN; MISFOLDED PROTEINS; NEURODEGENERATIVE DISORDERS; PROTEIN DYNAMICS; TAU PROTEINS;

BRAIN;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; PRION;

AGING; ALZHEIMER DISEASE; APOE E4 GENE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEGENERATIVE DISEASE; EDUCATIONAL STATUS; EPIDEMIC SPREADING MODEL; FEMALE; GENOTYPE; HUMAN; LIFE HISTORY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MILD COGNITIVE IMPAIRMENT; MOLECULAR DYNAMICS; NEUROPATHOLOGY; ONSET AGE; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN METABOLISM; REPRODUCIBILITY; SEX DIFFERENCE; VALIDATION PROCESS; ADOLESCENT; ADULT; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; EPIDEMIC; METABOLISM; MIDDLE AGED; PRION; YOUNG ADULT;

ADOLESCENT; ADULT; AGING; AMYLOID BETA-PEPTIDES; BRAIN; EPIDEMICS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PRIONS; PROTEIN FOLDING; YOUNG ADULT;

EID: 84912103003     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003956     Document Type: Article

References (102)

1. Dobson CM, (2002) Protein misfolding diseases: Getting out of shape. Nature 418: 729–730.
2. Dobson CM, (2003) Protein folding and misfolding. Nature 426: 884–890.
3. Reynaud E, (2010) Protein Misfolding and Degenerative Diseases. Nat Educ 3(9): 28.
4. Frost B, Diamond MI, (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155–159.
5. Brundin P, Melki R, Kopito R, (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev 11: 301–307.
6. Frost B, Jacks, R. & Diamond M, (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845–12852.
7. Jarrett JT, Berger EP, Lansbury PT, (1993) The Carboxy Terminus of the Amyloid Protein Is Critical for the Seeding of Amyloid Formation : Implications for the Pathogenesis of Alzheimer's Disease ? Am Chem Soc 32: 4693–4697.
8. Moreno-gonzalez I, Soto C, (2011) Seminars in Cell & Developmental Biology Misfolded protein aggregates : Mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol 22: 482–487.
9. Collins SR, Douglass A, Vale RD WJ, (2004) Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition. PLoS Biol 2: e321.
10. Hallbeck M, Nath S, Marcusson J, (2013) Neuron-to-neuron transmission of neurodegenerative pathology. Neuroscientist 19: 560–566.
11. Nath S, Agholme L, Kurudenkandy FR, Marcusson J, (2012) Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of beta-Amyloid and Martin Hallbeck. J Neurosci 32: 8767–8777.
12. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101–112.
13. Ittner LM, Jürgen G, (2011) Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12: 67–72.
14. Lloret A, Badia M-C, Giraldo E, Ermak G, Alonso M-D, et al. (2011) Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis 27: 701–709.
15. Giraldo E, Lloret A, Fuchsberger T, Viña J, (2014) Aβ and tau toxicities in Alzheimer's are linked via oxidative stress. Redox Biol 2: 873–877.
16. Shankar GM, Li S, Mehta TM, Al E, (2008) Amyloid-β protein dimers drom AD impair synaptic plasticity and memory. Nat Med 14, 8: 837–842.
17. Desrumaux C, Pisoni A, Meunier J, Deckert V, Athias A, et al. (2013) Increased amyloid-β peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice. Neuropsychopharmacology 38: 817–825.
18. Lloret A, Badía M-C, Mora NJ, Ortega A, Pallardó F V, et al. (2008) Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. Free Radic Biol Med 44: 2019–2025.
19. Song H-L, Shim S, Kim D-H, Won S-H, Joo S, et al. (2014) β-Amyloid is transmitted via neuronal connections along axonal membranes. Ann Neurol 75: 88–97.
20. Waters J, (2010) The concentration of soluble extracellular amyloid-β protein in acute brain slices from CRND8 mice. PLoS One 5: 15709.
21. Jucker M, Walker LC, (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501: 45–51.
22. Walker LC, LeVine H, (2012) Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 287: 33109–33115.
23. Braak H BE, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239–259.
24. Braak H, Ghebremedhin E, Rub U, Bratzke H DTK, (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121–134.
25. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP AN, (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990–1993.
26. Palop JJ, Chin J, Mucke L, (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443: 768–773.
27. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD, (2009) Neurodegenerative Diseases Target Large-scale Human Brain Networks. Neuron 62: 42–52.
28. Greicius MD, Srivastava G, Reiss AL M V, (2004) Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101: 4637–4642.
29. Buckner R, Snyder A, Shannon B, LaRossa G, Sachs R, et al. (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709–7717.
30. Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW, (2012) Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome. Neuron 73: 1216–1227.
31. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, et al. (2009) Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 29: 1860–1873.
32. De Haan W, Mott K, van Straaten ECW, Scheltens P, Stam CJ, (2012) Activity dependent degeneration explains hub vulnerability in Alzheimer's disease. PLoS Comput Biol 8: e1002582.
33. Stam CJ, Haan W De, Daffertshofer A, Jones BF, Manshanden I, et al. (2009) Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 132(1): 213–24.
34. Raj A, Kuceyeski A, Weiner M, (2012) A Network Diffusion Model of Disease Progression in Dementia. Neuron 73: 1204–1215.
35. Fiala M, Mahanian M, Mizwicki M, Tse E, et al. (2011) MGAT3 mRNA: a biomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids. J Alzheimers Dis 25: 135–144.
36. Cashman J, Ghirmai S, Abel K, Fiala M, (2008) Immune defects in Alzheimer's disease: new medications development. BMC Neurosci 9(2): S13.
37. Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78: 631–643.
38. Mawuenyega K, Sigurdson W, Ovod V, Munsell L, Kasten T, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012): 1774.
39. Domert J, Rao SB, Agholme L, Brorsson A-C, Marcusson J, et al. (2014) Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiol Dis 65: 82–92.
40. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5: e9505.
41. Grant J, Ghosn E, Axtell R, Herges K, Kuipers H, et al. (2012) Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 4(145): 145ra105.
42. Klein A, Tourville J, (2012) 101 Labeled Brain Images and a Consistent Human Cortical Labeling Protocol. Front Neurosci 6: 171.
43. Buckner R, Andrews-Hanna J, Schacter D, (2008) The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124: 1–38.
44. Andrews-Hanna J, Reidler J, Huang C, Buckner R, (2010) Evidence for the default network's role in spontaneous cognition. J Neurophysiol 104(1): 322–335.
45. Mevel K, Chételat G, Eustache F, Desgranges B (2011) The Default Mode Network in Healthy Aging and Alzheimer's Disease. Int J Alzheimers Dis, Article ID 535816.
46. Leech R, Sharp D, (2013) The role of the posterior cingulate cortex in cognition and disease. Brain 137(1): 12–32.
47. Rubinov M, Sporns O, (2011) Weight-conserving characterization of complex functional brain networks. Neuroimage 56: 2068–2079.
48. Snow J (1855) On the mode of communication of cholera. London J Churchill, 2.
49. Brockmann D, Helbing D, (2013) The hidden geometry of complex, network-driven contagion phenomena. Science 342: 1337–1342.
50. Van den Heuvel MP, Sporns O, (2013) Network hubs in the human brain. Trends Cogn Sci 17: 683–696.
51. Crossley N, Scott J, Carletti F, Fox PT, et al. (2014) The hubs of the human connectome are generally implicated in the anatomy of brain disorders. Brain 137(8): 2382–2395.
52. Hardy J, Higgins G, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184–185.
53. Karran E, Mercken M, De Strooper B, (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698–712.
54. Ramanan V, Risacher S, Nho K, Kim S, Swaminathan S, et al. (2013) APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry 19: 351–357.
55. Holtzman D, Morris J, Goate A, (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr71.
56. Castellano J, Kim J, Stewart F, Jiang H, DeMattos R, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3: 89.
57. Koffie R, Hashimoto T, Tai H, Kay K, Serrano-Pozo A, et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135: 2155–2168.
58. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (80) 261: 921–923.
59. Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro M, et al. (2005) Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 76(1): 15–23.
60. Genin E, Hannequin D, Wallon D, Sleegers K, Al E, (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9): 903–907.
61. Damoiseaux J, Seeley W, Zhou J, Shirer W, Coppola G, et al. (2012) Gender Modulates the APOE E4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels. J Neurosci 32(24): 8254–8262.
62. Farrer L, Cupples L, Haines J, Hyman B, Kukull W, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349–1356.
63. Corder E, Ghebremedhin E, Taylor M, Thal D, Ohm T, et al. (2004) The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci 1019: 24–28.
64. Rodrigue K, Kennedy K, Park D, (2009) Beta-Amyloid Deposition and the Aging Brain. Neuropsychol Rev 19(4): 436–450.
65. Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509–1517.
66. Kemppainen N, Aalto S, Karrasch M, Någren K, Savisto N, et al. (2008) Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 63: 112–118.
67. Rolstad S, Nordlund A, Eckerström C, Gustavsson M, Zetterberg H, et al. (2009) Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment—proof of concept. Dement Geriatr Cogn Disord 27: 194–200.
68. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403–413.
69. Jack CR, JrKnopman DS, Jagust WJ, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119–128.
70. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207–216.
71. Small S, Duff K, (2008) Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60: 534–542.
72. Metcalf DJ, García-Arencibia M, Hochfeld WE, Rubinsztein DC, (2012) Autophagy and misfolded proteins in neurodegeneration. Exp Neurol 238: 22–28.
73. Palop J, Mucke L, (2010) Amyloid-β Induced Neuronal Dysfunction in Alzheimer's Disease: From Synapses toward Neural Networks. Nat Neurosci 13(7): 812–818.
74. Estrada E, Kalala-mutombo F, Valverde-colmeiro A, (2011) Epidemic spreading in networks with nonrandom long-range interactions. Phys Rev E 036110: 1–15.
75. Iturria-medina Y, (2013) Anatomical Brain Networks on the Prediction of Abnormal Brain States. Brain Connectivity 3(1): 1–21.
76. Evans A, (2013) Networks of anatomical covariance. Neuroimage 80: 489–504.
77. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, et al. (2010) 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4): 363–372.
78. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, et al. (2013) Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5: 189.
79. Wildsmith K, Holley M, Savage J, Skerrett R, Landreth G, (2013) Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers Res Ther 5(4): 33.
80. Wisniewski T, Goñi F, (2014) Immunotherapy for Alzheimer's disease. Biochem Pharmacol 88: 499–507.
81. Cramer P, Cirrito J, Wesson D, Lee C, Karlo J, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335(6075): 1503–1506.
82. Jones DK, Cercignani M, (2010) Twenty-five pitfalls in the analysis of diffusion MRI data. NMR Biomed 23: 803–820.
83. Iturria-Medina Y, Canales-Rodríguez EJ, Melie-García L, Valdés-Hernández PA, Martínez-Montes E, et al. (2007) Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. Neuroimage 36: 645–660.
84. Zalesky A, Fornito A, Harding IH, Cocchi L, Yücel M, et al. (2010) Whole-brain anatomical networks: Does the choice of nodes matter? Neuroimage 50: 970–983.
85. Caspers S, Eickhoff SB, Zilles K, Amunts K, (2013) Microstructural grey matter parcellation and its relevance for connectome analyses. Neuroimage 80: 18–26.
86. Lotka A (1925) Elements of physical biology. Williams Wilkins, Balt.
87. Volterra V, (1926) Variazioni e fluttuazioni del numero d′individui in specie animali conviventi. Lincei, Mem R Accad Naz dei 2: 31–113.
88. http://adni.loni.usc.edu.
89. http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Data_Use_Agreement.pdf.
90. http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Manuscript_Citations.pdf.
91. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, (2005) The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci 14: 1753–1759.
92. Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, (1995) A Probablistic Atlas of the Human Brain: Theory and Rationale for Its Development. Neuroimage 2: 89–101.
93. Gini C (1912) Variability and Mutability. C Cuppini, Bol: 156 pages.
94. Lundmark K, Westermark G, Nystrom S, Murphy C, Solomon A, et al. (2002) Transmissibility of systemic a myloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99(10): 6979–6984.
95. Cui D, Kawano H, Takahashi M, Hoshii Y, Setoguchi M, et al. (2002) Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol Int 52(4): 264.
96. Jagust W, Bandy D, Chen K, Foster N, Landau S, et al. (2010) The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement 6: 221–229.
97. Evans A, Kamber M, Collins D, Macdonald D (1994) An MRI-based probabilistic atlas of neuroanatomy. S Shorvon, D Fish, F Andermann, G Bydder H Stefan, Ed Magn Reson Scanning Epilepsy, Plenum, New York: 263–274.
98. Yeh F, Tseng W, (2011) NTU-90: a high angular resolution brain atlas constructed by q-space diffeomorphic reconstruction. Neuroimage 58(1): 91–99.
99. Olsson A, Vanderstichele H, Andreasen N, DeMeyer G, Wallin A, et al. (2005) Simultaneous measurement of ß-amyloid1-42 in CSF by xMAP technology. Clin Chem 51: 336–345.
100. Shaw L, Vanderstichele H, Knapik-Czajka, Figurski M, Coart E, et al. (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropath 121: 597–609.
101. Lindeman R, Merenda P, Gold R, (1980) Introduction to Bivariate and Multivariate Analysis. Scott, Foresman, Glenview IL: 119.
102. Grömping U, (2006) Relative Importance for Linear Regression in R : The Package relaimpo. J Stat Sofw 17 (1).